Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Panblok H7 + MF59
- Development stage
- Phase 2
- Lead developer
- Parent
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Panblok H7 + MF59 is a combination vaccine consisting of the recombinant hemagglutinin (rHA) antigen from the influenza A/H7 virus (Panblok H7) formulated with the oil-in-water emulsion adjuvant MF59. The vaccine is designed to induce an immune response against avian-origin influenza A(H7N9) and related strains. The addition of the MF59 adjuvant enhances immunogenicity by promoting stronger antibody responses and enabling antigen dose sparing compared to unadjuvanted formulations. Mechanistically, the rHA component elicits neutralizing antibodies targeting viral hemagglutinin, while the MF59 adjuvant acts by recruiting immune cells to the injection site and enhancing antigen presentation through induction of chemokines and cytokines[1][2][3]. This combination has been evaluated in clinical trials for safety and immunogenicity in adults across various age groups[1][3][4].
- Brand names
- Panblok H7 + MF59
- Other names
- recombinant H7 influenza vaccine adjuvanted with MF59Panblok + MF59
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on Panblok H7 + MF59.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Panblok H7 + MF59.